Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Randomized Phase 2/3 BTC study data disclosed, potentially material to Compass Therapeutics’ clinical and valuation outlook.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Randomized Phase 2/3 BTC study data disclosed, potentially material to Compass Therapeutics’ clinical and valuation outlook
- Management webcast scheduled April 27, 2026 at 8:00 a.m. ET to review trial results
- Full press release and presentation filed as Exhibits 99.1 and 99.2 for detailed efficacy and safety analysis
Item 8.01 · Other Events
- COMPANION-002 met its ORR endpoint: 17.1% versus 5.3% for paclitaxel, including one complete response
- Median PFS improved to 4.7 months versus 2.6 months, with HR 0.44 and p<0.0001
- OS endpoint not met, largely confounded by 54% control-arm crossover to tovecimig
- Crossover patients showed median OS 12.8 months versus 6.1 months for non-crossover patients
- FDA discussions planned ahead of a BLA submission, but regulatory approval remains uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.